Hemochromatosis-Associated Mortality in the United States from 1979 to 1992: An Analysis of Multiple-Cause Mortality Data
- 1 December 1998
- journal article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 129 (11_Part_2) , 946-953
- https://doi.org/10.7326/0003-4819-129-11_part_2-199812011-00005
Abstract
Hemochromatosis, which can lead to serious chronic diseases resulting from iron overload, has an estimated prevalence of 50 to 80 cases per 10 000 persons. However, little population-based information is available on the impact of hemochromatosis on morbidity and mortality. To evaluate trends over 14 years in deaths and medical conditions associated with hemochromatosis in the United States. We searched Multiple-Cause Mortality Files compiled by the National Center for Health Statistics for the years 1979 to 1992 for all records listing hemochromatosis. We used these data to calculate age-adjusted and age-specific mortality rates, identify medical conditions associated with a known diagnosis of hemochromatosis at death, and calculate proportionate mortality ratios for these medical conditions. The listing of hemochromatosis on death certificates increased 60% from 1979 to 1992. Decedents with hemochromatosis were 23, 13, and 5 times more likely to have liver neoplasms, liver disease, and cardiomyopathy, respectively, than were decedents without hemochromatosis. Conversely, decedents with liver neoplasms, liver disease, and cardiomyopathy were 26, 14, and 5 times more likely, respectively, to have hemochromatosis than were decedents without these conditions. Hemochromatosis was 82 times more likely in persons with the combination of liver neoplasms and diabetes and 43 times more likely in those with the combination of liver disease and diabetes than in those without these conditions. Comparison of the reported prevalence of hemochromatosis among decedents with estimates of prevalence in the general U.S. population suggests that either the penetrance or the recognition of hemochromatosis, or both, is low. Nevertheless, substantial mortality resulting from liver disease, liver neoplasms, cardiomyopathy, and a combination of liver disease and diabetes in patients with hemochromatosis argues for the improved diagnosis and treatment of hemochromatosis in persons with these conditions.Keywords
This publication has 34 references indexed in Scilit:
- The iron paradigm of ischemic heart diseasePublished by Elsevier ,2004
- Trends and patterns of mortality associated with birth defects and genetic diseases in the United States, 1979–1992: An analysis of multiple-cause mortality dataGenetic Epidemiology, 1997
- Hereditary hemochromatosisClinica Chimica Acta; International Journal of Clinical Chemistry, 1996
- Iron overload in African AmericansThe American Journal of Medicine, 1995
- Body iron stores and risk of cancerInternational Journal of Cancer, 1994
- Moderate elevation of body iron level and increased risk of cancer occurrence and deathInternational Journal of Cancer, 1994
- Hereditary HemochromatosisPublished by American Medical Association (AMA) ,1993
- Hemochromatosis and dietary iron supplementation: Implications from US mortality, morbidity, and health survey dataJournal of the American Dietetic Association, 1992
- Sickle cell disease and hemochromatosisAmerican Journal of Hematology, 1991
- Expression of hemochromatosis in homozygous subjectsGastroenterology, 1990